RUBY's Business Model
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Sector & Industry | Healthcare / Biotechnology |
Website | https://www.rubiustx.com |
CEO (Chief Executive Officer) | Laurence A. Turka |
Number of Employees | |
IPO date | July 18, 2018 |
RUBY Latest News
|
|
|
|
|
Contact | |
---|---|
Country | US |
Address | 399 Binney Street |
City | Cambridge |
State | MA |
Phone | 617 679 9600 |
Zip Code | 02139 |
Other Identifiers | |
CIK | 0001709401 |
ISIN | US78116T1034 |
CUSIP | 78116T103 |
Open | 0.0555 |
Previous Close | 0.0555 |
Volume | 755.9 Thou. |
Average Volume | 99.53 Thou. |
Day’s Range | 0.055 – 0.057 |
52 Week Range | 0.0032-0.3763 |
MA (50) | 0.021742 |
MA (200) | 0.01987485 |
Market Cap | 0 |
Shares Out. | 0 |
Earnings Date | Feb 26, 2024 |
Beta | |
Last Dividend | |
EPS | |
PE | |